These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 20668141

  • 1. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK, Liu SJ, Cheung TH, Yeo W, Ngai SM, Cheung JL, Chong P, Man S.
    Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
    [Abstract] [Full Text] [Related]

  • 2. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
    Chan PK, Liu SJ, Cheung JL, Cheung TH, Yeo W, Chong P, Man S.
    J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
    [Abstract] [Full Text] [Related]

  • 3. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, Saito T, Sato N.
    Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
    [Abstract] [Full Text] [Related]

  • 4. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
    Cheng WF, Lee CN, Su YN, Chang MC, Hsiao WC, Chen CA, Hsieh CY.
    Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
    [Abstract] [Full Text] [Related]

  • 5. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
    Kadish AS, Ho GY, Burk RD, Wang Y, Romney SL, Ledwidge R, Angeletti RH.
    J Natl Cancer Inst; 1997 Sep 03; 89(17):1285-93. PubMed ID: 9293919
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.
    Cancer Immunol Immunother; 2004 Jul 03; 53(7):642-50. PubMed ID: 14985860
    [Abstract] [Full Text] [Related]

  • 7. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y, Choi JW, Kim HJ, Eddouzi J, Kim SC, Ju W, Kim YH, Kim HJ.
    Cancer Med; 2018 Nov 03; 7(11):5655-5664. PubMed ID: 30353680
    [Abstract] [Full Text] [Related]

  • 8. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
    Sarkar AK, Tortolero-Luna G, Follen M, Sastry KJ.
    Gynecol Oncol; 2005 Dec 03; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
    [Abstract] [Full Text] [Related]

  • 9. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J.
    Clin Cancer Res; 2000 Sep 03; 6(9):3406-16. PubMed ID: 10999722
    [Abstract] [Full Text] [Related]

  • 10. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    J Virol; 2009 Jul 03; 83(13):6779-89. PubMed ID: 19386711
    [Abstract] [Full Text] [Related]

  • 11. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.
    Bourgault Villada I, Moyal Barracco M, Berville S, Bafounta ML, Longvert C, Prémel V, Villefroy P, Jullian E, Clerici T, Paniel B, Maillère B, Choppin J, Guillet JG.
    Clin Exp Immunol; 2010 Jan 03; 159(1):45-56. PubMed ID: 19843089
    [Abstract] [Full Text] [Related]

  • 12. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.
    Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M.
    Cancer Immunol Immunother; 2012 Jan 03; 61(1):63-70. PubMed ID: 21842207
    [Abstract] [Full Text] [Related]

  • 13. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
    Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M, Albert Einstein Cervix Dysplasia Clinical Consortium.
    Cancer Epidemiol Biomarkers Prev; 2002 May 03; 11(5):483-8. PubMed ID: 12010863
    [Abstract] [Full Text] [Related]

  • 14. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S, Akatsuka Y, Nawa A, Kondo E, Kiyono T, Torikai H, Nakanishi T, Ito Y, Tsujimura K, Iwata K, Ito K, Kodera Y, Morishima Y, Kuzushima K, Takahashi T.
    Int J Cancer; 2007 Feb 01; 120(3):594-604. PubMed ID: 17096336
    [Abstract] [Full Text] [Related]

  • 15. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
    Passmore JA, Milner M, Denny L, Sampson C, Marais DJ, Allan B, Gumbi PP, Hitzeroth II, Rybicki EP, Williamson AL.
    Immunology; 2006 Dec 01; 119(4):507-14. PubMed ID: 17026720
    [Abstract] [Full Text] [Related]

  • 16. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JM, Remmink AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ.
    J Gen Virol; 1996 Sep 01; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [Abstract] [Full Text] [Related]

  • 17. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.
    Persson M, Brismar Wendel S, Ljungblad L, Johansson B, Weiderpass E, Andersson S.
    Oncol Rep; 2012 Jul 01; 28(1):346-52. PubMed ID: 22484610
    [Abstract] [Full Text] [Related]

  • 18. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM.
    J Infect Dis; 1997 Apr 01; 175(4):927-31. PubMed ID: 9086151
    [Abstract] [Full Text] [Related]

  • 19. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination.
    Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H, Müller RT, Jochmus I, Gissmann L, Schneider A, Dürst M.
    Int J Cancer; 2001 Apr 15; 92(2):285-93. PubMed ID: 11291058
    [Abstract] [Full Text] [Related]

  • 20. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
    van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH.
    Int J Cancer; 2006 Feb 01; 118(3):675-83. PubMed ID: 16108057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.